St. Louis, MO
Home ► Personal Injury Lawyer – All of your Legal Questions Answered ► Do I Qualify to Participate in a Bad Drug Lawsuit? ► Invokana Lawsuit
Patients who have previously been prescribed Invokana -- or similar SGLT-2 inhibitor -- and been injured by the drug may be eligible to participate in an Invokana lawsuit.
February 2019 - Recently, we learned of a new injury that can be related to Invokana use. Genital gangrene, sometimes known as Fournier’s gangrene or necrotizing fasciitis of the genital region, can be caused by SGLT2 inhibitors like Invokana, Farxiga, and Jardiance. This condition is rare, but if you have experienced it while using one of these drugs, please let us know.
August 2018 - TorHoerman Law is currently evaluating cases for individuals who underwent toe, foot, or leg amputations while on Invokana.
Invokana, approved by the U.S. Food and Drug Administration (FDA) in 2013, is part of a class of Type 2 diabetes drugs called sodium-glucose cotransporter-2 (SGLT-2) inhibitors. SGLT-2 is a protein in humans that facilitates glucose reabsorption in the kidneys, and SGLT-2 inhibitors block the reabsorption of glucose in the kidneys, increase glucose excretion, and in turn lower blood glucose levels. SGLT-2 inhibitors are commonly used to treat adults with Type 2 diabetes.
Studies and trials have shown Invokana, and similar SGLT-2 drugs to be highly effective in controlling blood glucose levels and lowering hemoglobin levels for patients with Type 2 diabetes.
Because of its effectiveness, the popularity of Invokana has increasingly grown since its market introduction. Invokana is considered the most popular drug in its class.
However, Invokana and similar medications have been linked to a number of dangerous and potentially life-threatening adverse health effects.
Invokana was the first drug of its class, approved for market in 2013. Invokana is manufactured by Johnson & Johnson subsidiary, Janssen Pharmaceuticals. Invokamet was approved in 2014. Invokamet XR was approved in 2016.
Despite its notable ability to control blood sugar levels, Invokana has some potentially serious side effects:
Starting in 2015, the FDA began to release multiple public safety announcements, warning the public of the links between Invokana/SGLT-2’s and these dangerous adverse effects.
Following the release of Invokana, the FDA approved drugs in the same SGLT-2 class. All though they carry a different brand name, these follow-up drugs carry the same risks and warnings as Invokana and Invokamet. These follow-up SGLT-2 inhibitors also include:
Farxiga was first approved for market in 2014, after being rejected for approval by the FDA in multiple prior pre-market trial phases.
Farxiga is similar to most other SGLT2 inhibitors, with the distinction of being five times more likely to cause bladder cancer. Farxiga may also increase the progression of bladder cancers in patients who are prone to bladder cancer, according to studies conducted by the Cancer Prevention & Treatment Fund
A conglomeration of patients have filed an Invokana lawsuit against the manufacturer, Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.
The Invokana lawsuit claims Invokana/Janssen:
If you or a loved one was taking Invokana (or a similar SGLT-2) to treat Type 2 diabetes and suffered injuries from the drug, you may be entitled to compensation for your damages with a Type 2 diabetes lawsuit.
Do you have questions about the Invokana lawsuit? Contact TorHoerman Law.
July 6, 2017 - The FDA issued an Invokana black box warning alerting consumers of the higher risks of lower limb amputation for patients using SGLT-2 inhibitors. The risks of amputation were twice as high for patients using Invokana or similar SGLT-2 inhibitors.
June 8, 2017 - A new study published in the New England Journal of Medicine showed that SGLT2 inhibitors doubled the risk for Diabetic ketoacidosis when compared to DPP-4 inhibitors.
June 2016 - The FDA introduced a new warning for Invokana, Invokamet, Farxiga, and Xigduo XR, linking the SGLT-2 inhibitors to reports of acute kidney injury that required hospitalization in some cases.
May 2016 - The FDA issued a consumer safety alert for SLGT-2 inhibitors.
September 2015 - The FDA revised the Invokana and Invokamet labels to include information about the risk of bone fracture.
May 2015 - The FDA issued a drug safety communication stating that Invokana, Farxiga, and Jardiance may lead to ketoacidosis, and highlighted 20 cases of acidosis in patients treated with SGLT-2 inhibitors from March 2013 to June 2014.
Contact us by phone at 1-888-508-6752 or email us below.
Your information will be used only so that we may contact you to evaluate your case. Your contact information will never be shared or sold to anyone other than TorHoerman Law.
© 2017 TorHoerman Law LLC.
The contents of this webpage have been prepared by TorHoerman Law, LLC for informational purposes only. None of this information is intended as either legal or medical advice or opinions. No attorney/client relationship is established with use of this website. Sending or receiving information through this site, posting to our blogs/news site does not establish an attorney/client relationship. An attorney/client relationship with TorHoerman Law is established only by an express and written agreement by TorHoerman Law to represent you. Our attorneys make a case-by-case assessment of any claims and results may vary depending on the facts concerning any case. The attorneys at TorHoerman Law are licensed to practice in Illinois, Missouri, and California. In some circumstances, cases may be sent to other qualified lawyers. In those circumstances, TorHoerman Law maintains joint responsibility.
Wesite Design & Development by Kaizen Coding